{"id":561642,"date":"2025-11-17T00:00:00","date_gmt":"2025-11-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2025-biopharma-irritable-bowel-syndrome-current-treatment-treatment-algorithms-claims-data-analysis-ibs-2\/"},"modified":"2026-03-31T10:24:16","modified_gmt":"2026-03-31T10:24:16","slug":"algoim0056-2025-biopharma-irritable-bowel-syndrome-current-treatment-treatment-algorithms-claims-data-analysis-ibs","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2025-biopharma-irritable-bowel-syndrome-current-treatment-treatment-algorithms-claims-data-analysis-ibs\/","title":{"rendered":"Irritable Bowel Syndrome &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; IBS-Constipation (Including IBS Without Diarrhea) (US)"},"content":{"rendered":"<p>Irritable bowel syndrome (<abbr title=\"irritable bowel syndrome\">IBS<\/abbr>) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. <abbr title=\"International Statistical Classification of Diseases and Related Health Problems\">ICD<\/abbr> codes for <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> include a variety of subtypes; this analysis covers constipation-predominant <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> (<abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr>) and <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea. Limited treatment options are available, and only a few drugs have <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval for <abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr>. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan\u2019s Linzess and Synergy Pharmaceutical\u2019s Trulance), bicyclic fatty acids (Takeda\u2019s Amitiza and Par\u2019s generic lubiprostone), and sodium\/hydrogen exchanger 3 (<abbr title=\"sodium-hydrogen exchanger 3\">NHE3<\/abbr>) inhibitors (Ardelyx\u2019s Ibsrela). These treatments are only moderately effective. Zelnorm, a <abbr title=\"serotonin 4 receptor\">5-HT4<\/abbr> receptor agonist, was relaunched in 2019 for <abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr> in women younger than age 65 but was removed from the market again in 2022 for business-related reasons.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr> (including <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea) patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr> (including <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea) patients?<\/li>\n<li>How has Linzess been integrated into the treatment algorithm, and what is its source of business? Do Linzess, Trulance, and the newly launched generic lubiprostone continue to gain patient share?<\/li>\n<li>What percentage of <abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr> patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Real-world data: <\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key drugs covered: <\/strong>lbsrela, Linzess, Trulance, Amitiza, lubiprostone (generic), <abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s, <abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s, tricyclic agents, anticholinergics<\/p>\n<p><strong>Key analyses<\/strong>: Brand \/ therapy usage across patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flow charts<\/p>\n<p><strong>Key feature: <\/strong>Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-561642","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastrointestinal","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/561642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/561642\/revisions"}],"predecessor-version":[{"id":561842,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/561642\/revisions\/561842"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=561642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}